Evidence map›Paper›PMID 33650044›Full record

ArticleVirchows Archiv : an international journal of pathology2021

Loss of CTNNB1 exon 3 in sclerosing angiomatoid nodular transformation of the spleen.

Sarp Uzun, Özge Özcan, Aynur Işık, Arzu Sağlam, Gökhan Gedikoğlu, Ahu Senem Demiröz, Işınsu Kuzu, Ayşegül Üner, Aytekin Akyol

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Sarp UzunTumor Biology and Immunology PhD Program, Department of Basic Oncology, Hacettepe University Cancer Institute, Sıhhiye, 06100, Ankara, Turkey.
Özge ÖzcanStem Cell Sciences PhD Program, Department of Stem Cell, Hacettepe University Faculty of Sciences, Sıhhiye, 06100, Ankara, Turkey.
Aynur IşıkHacettepe University Transgenic Animal Technologies Research and Application Center, Sıhhiye, 06100, Ankara, Turkey.
Arzu SağlamDepartment of Pathology, Hacettepe University Faculty of Medicine, Sıhhiye, 06100, Ankara, Turkey.
Gökhan GedikoğluDepartment of Pathology, Hacettepe University Faculty of Medicine, Sıhhiye, 06100, Ankara, Turkey.
Ahu Senem DemirözDepartment of Pathology, İstanbul University-Cerrahpaşa Faculty of Medicine, Fatih, 34098, İstanbul, Turkey.
Işınsu KuzuDepartment of Pathology, Ankara University Faculty of Medicine, Sıhhiye, 06230, Ankara, Turkey.
Ayşegül ÜnerDepartment of Pathology, Hacettepe University Faculty of Medicine, Sıhhiye, 06100, Ankara, Turkey.
Aytekin AkyolHacettepe University Transgenic Animal Technologies Research and Application Center, Sıhhiye, 06100, Ankara, Turkey. aytekina@hacettepe.edu.tr.ORCID http://orcid.org/0000-0002-4075-3475
Hacettepe University · TRHacettepe University Hospital · TRAnkara University · TRIstanbul University-Cerrahpaşa · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sclerosing angiomatoid nodular transformation (SANT) is a rare vascular lesion of the spleen. Although several hypotheses have been suggested, the etiopathogenesis of SANT remains unknown. It is also unclear whether SANT is a reactive or a neoplastic lesion. Since CTNNB1 (β-catenin gene) exon 3 mutations were frequently detected in some rare fibrovascular lesions, we aimed to investigate the presence of oncogenic CTNNB1 mutations in SANT cases. For this purpose, 7 cases of SANT with typical histopathological features were retrieved. First, the presence of CTNNB1 exon 3 alterations was examined with a recently described immunohistochemistry-based method. Then, the findings were confirmed with polymerase chain reaction (PCR), reverse transcription PCR (RT-PCR), and Sanger sequencing. In all cases, immunochemistry of β-catenin gave a staining pattern that was suggestive of exon 3 alteration; however, no missense mutations were found in any case at the CTNNB1 exon 3 hotspot region. Subsequently, we screened for large interstitial deletions of CTNNB1 exon 3 which revealed short PCR products in three cases. Sequencing confirmed that these cases had large interstitial deletions, resulting in loss of the entire exon 3 of CTNNB1. In the remaining four cases, loss of exon 3 was documented at the cDNA level, although genomic deletion was not identified. These results demonstrate that loss of CTNNB1 exon 3 and stabilization of β-catenin with activation of Wnt signaling pathway might have a significant role in the pathogenesis of SANT. Through this study, we provided important evidence for the neoplastic nature and pathogenesis of this disorder.

Indexed as

AdultAgedbeta CateninExonsFemaleHistiocytoma, Benign FibrousHumansImmunohistochemistryMaleMiddle AgedOncogenesRetrospective StudiesSclerosing SolutionsSpleenSplenic NeoplasmsWnt Signaling Pathwaybeta CateninCTNNB1 protein, humanSclerosing SolutionsCTNNB1Exon 3Sclerosing angiomatoid nodular transformation of spleenWntβ-Catenin

Identifiers

PMID33650044
OpenAlexW3135659793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.